Comparing with other subtypes of breast cancer, TNBC has increased immunogenicity, such as heavier tumor mutation load, more tumor-infiltrating lymphocytes, and higher positive rate of programmed death ligand-1 (PD-L1), suggesting that treatment with immune checkpoint inhibitors is more effective for patients with TNBC (Zhu et al., 2021). Here, CD274 is linked to neoplasm.